MEI Pharma, Inc. Share Price London S.E.
Equities
0JW9
US55279B3015
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.336 USD | -91.91% | +37.65% | -25.50% |
Sales 2024 * | 6.53Cr 542.54Cr | Sales 2025 * | 62.5L 52Cr | Capitalization | 2.07Cr 171.62Cr |
---|---|---|---|---|---|
Net income 2024 * | 2.6Cr 216.03Cr | Net income 2025 * | -4Cr -332.35Cr | EV / Sales 2024 * | 0.32 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.3 x |
P/E ratio 2024 * |
0.86
x | P/E ratio 2025 * |
-0.54
x | Employees | 46 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on MEI Pharma, Inc.
1 day | -91.91% | ||
1 week | +37.65% | ||
Current month | +42.16% | ||
1 month | +34.13% | ||
3 months | +0.37% | ||
6 months | -34.30% | ||
Current year | -25.50% |
Managers | Title | Age | Since |
---|---|---|---|
David Urso
CEO | Chief Executive Officer | 60 | 07/14/07 |
Justin File
DFI | Director of Finance/CFO | 53 | 12/23/12 |
Caroline Ruiz
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 26/18/26 |
Thomas Reynolds
BRD | Director/Board Member | 65 | 11/13/11 |
Charles Baltic
CHM | Chairman | 63 | 20/11/20 |
Date | Price | Change | Volume |
---|---|---|---|
24/24/24 | 3.14 | -.--% | 451 |
22/24/22 | 3.14 | -0.63% | 160 |
Delayed Quote London S.E., March 01, 2023 at 08:05 pm IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+44.98% | 4.05TCr | |
-10.87% | 2.72TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- MEIP Stock
- 0JW9 Stock